癌症患者下腔静脉滤器置入:谁应获益?
该回顾性单中心10年分析评估了250例癌症患者置入下腔静脉滤器的结局及与生存相关的术前变量。约31.2%符合早期死亡标准,体重指数>18 kg/m2、无转移性疾病及在另一次手术同期置入滤器与更高生存机会相关。结论建议置入前进行多学科评估,对存活患者积极启动滤器回收流程。
要点
- 癌症患者置入下腔静脉滤器前应多学科评估整体状况,必要时考虑姑息治疗。
- 体重指数>18 kg/m2、无转移及围手术期置入滤器(尤其择期根治手术)与更高生存相关。
- 存活患者应实施积极的滤器回收排查方案。
核心结论
- 严重肿瘤病例置入下腔静脉滤器前应基于整体状况进行多学科评估,并可能考虑姑息治疗。
- 3年或5年生存机会更大的患者似乎是那些在另一次手术围手术期置入滤器(尤其择期根治手术)、无营养不良且当时无转移性疾病者。
- 对存活患者应实施积极的滤器回收排查方案。
研究设计与样本
- 回顾性单中心10年期间分析,纳入接受下腔静脉滤器置入的癌症患者约250例。
- 早期死亡定义为滤器置入后30天内或同一住院期间发生的死亡。
主要发现
- 女性占51.6%,77.2%有近端下肢深静脉血栓,34.8%有抗凝禁忌,32.8%在抗凝开始后出现出血,18.4%因即将手术且术后不能立即抗凝而置入滤器。
- 51.2%的滤器为可回收型,但仅2例取出。
- 59.2%在滤器置入时已有转移性疾病,31.2%符合早期死亡标准;其中34例在滤器置入后转入姑息治疗(中位13.5天)。
- 体重指数>18 kg/m2、无转移性疾病及在另一次手术同期麻醉下置入滤器(尤其择期根治手术)与更高生存机会相关。
临床怎么用
- 癌症患者置入下腔静脉滤器前应进行多学科评估,综合整体状况决定是否置入或考虑姑息治疗。
- 对存活患者应主动排查并实施滤器回收。
局限性
- 回顾性单中心分析,可能存在选择偏倚和资料不完整。
- 可回收滤器取出率极低(仅2例),回收流程执行不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for venous thromboembolism is anticoagulation; vena cava filter placement is an alternative in special situations. We aimed to evaluate the outcomes in patients with cancer undergoing filter placement in a cancer center during a 10-year period and assess which preoperatory variables were associated with poorer survival. METHODS: Retrospective unicenter analysis during a 10-year period was carried out in patients with cancer who had undergone placement of vena cava filter. Early deaths were those that occurred less than 30 days after the filter placement or that occurred during the same hospital stay of the placement. RESULTS: About 250 patients were analyzed. About 51.6% were females; 77.2% had proximal lower limb deep vein thrombosis; 34.8% had contraindications to anticoagulation; 32.8% presented bleeding after the onset of anticoagulation; and 18.4% had the filter implanted because they were going to undergo surgery and could not be anticoagulated immediately after. About 51.2% of the filters were removable. However, only 2 had the filter removed. About 59.2% had metastatic disease at the time of filter placement. About 31.2% fulfilled criteria for early death. Of those, 34 patients were put in palliative care after filter insertion (median, 13.5 days). Body mass index >18 kg/m2, the absence of metastatic disease, and filter placement during the same anesthesia of another surgery (especially if elective and curative) were associated with a higher chance of survival. CONCLUSIONS: Multidisciplinary evaluation (and possibly consideration for palliation) should take place before the decision to insert a vena cava filter in severe oncologic cases depending on overall status. Patients with a greater chance of survival at a 3 or 5 years interval seem to be those whose filters were placed in the perioperative context of other surgeries (specially elective and curative), who were not undernourished, and whose disease was not metastatic at that time. For patients who survived, an active investigation protocol for filter removal should be implemented.
引用
- Teivelis MP, Schettini IH, Pignataro BS, et al. Inferior Vena Cava Filter in Cancer Patients: On Whom Should We Be Placing Them? Ann Vasc Surg. 2020. PMID: 32891742. doi:10.1016/j.avsg.2020.08.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。